Metabolic syndrome in castration‐resistant prostate cancer patients treated with abiraterone. Issue 12 (15th May 2015)

• Record Type: Journal Article
• Authors: Conteduca, Vincenza; Caffo, Orazio; Derosa, Lisa; Veccia, Antonello; Petracci, Elisabetta; Chiuri, Vincenzo Emanuele; Santoni, Matteo; Santini, Daniele; Fratino, Lucia; Maines, Francesca; Testoni, Sara; De Giorgi, Ugo
• Is Part Of: Prostate. Volume 75:Issue 12(2015)
• Page Start: 1329
• Page End: 1338
• Publication Date: 2015-05-15
• Subjects: Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.23014
• Languages: English
• ISSNs: 0270-4137

Abstract

<abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="pros23014-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>Metabolic syndrome (MS) has not yet been studied in castration‐resistant prostate cancer (CRPC) men treated with novel hormonal therapies. The study aims to assess the impact of MS on outcome from time starting abiraterone.</p> </sec> <sec id="pros23014-sec-0002" sec-type="section"> <title>PATIENTS AND METHODS</title> <p>We retrospectively evaluated a consecutive series of metastatic CRPC patients treated with abiraterone after docetaxel failure. MS, as defined by modified Adult Treatment Panel (ATP) III criteria, was assessed at the time of initiation of abiraterone, during treatment and follow‐up.</p> </sec> <sec id="pros23014-sec-0003" sec-type="section"> <title>RESULTS</title> <p>Sixty‐seven of 178 patients evaluated (37.6%) met MS criteria at baseline, before abiraterone initiation, whereas for 11 (9.9%) without MS before treatment with abiraterone this occurred during treatment. Median PFS was equal to 4.7 months for patients with MS versus 9 months for those without MS. Patients with MS had an increased risk of 71% of progression or death for all causes than patients without MS (HR = 1.7, 95% CI [1.2–2.4], <italic>P</italic> = 0.03). Median OS was 14.7 months and 22.3 months in patients with and without MS, respectively. After adjusting for covariates, MS resulted not significantly associated to OS (HR = 1.42, 95% CI [0.91–2.22], <italic>P</italic> = 0.073).</p> </sec> <sec id="pros23014-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>The presence of MS is a significant risk factor for shorter PFS in CRPC patients treated with abiraterone, even if it does not show a significant impact on OS. A prospective evaluation is warranted. <italic>Prostate 75:1329–1338, 2015</italic>. © 2015 Wiley Periodicals, Inc.</p> </sec> </abstract>